Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
80.38
+0.91 (1.15%)
Dec 5, 2025, 4:00 PM EST - Market closed
Monopar Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 127.68 | 45.82 | 7.27 | 8.19 | 20.3 | 16.74 | Upgrade
|
| Short-Term Investments | 16 | 14.4 | - | 4.93 | - | - | Upgrade
|
| Cash & Short-Term Investments | 143.68 | 60.21 | 7.27 | 13.12 | 20.3 | 16.74 | Upgrade
|
| Cash Growth | 2286.61% | 728.67% | -44.62% | -35.38% | 21.31% | 26.66% | Upgrade
|
| Other Current Assets | 0.41 | 0.08 | 0.07 | 0.05 | 0.22 | 0.06 | Upgrade
|
| Total Current Assets | 144.09 | 60.29 | 7.33 | 13.17 | 20.52 | 16.8 | Upgrade
|
| Property, Plant & Equipment | 0.11 | - | 0.01 | 0.06 | - | - | Upgrade
|
| Other Long-Term Assets | - | - | - | - | - | 0.07 | Upgrade
|
| Total Assets | 144.2 | 60.29 | 7.35 | 13.23 | 20.52 | 16.87 | Upgrade
|
| Accounts Payable | 2.54 | 2.25 | 1.76 | 3.13 | 1.58 | 1.18 | Upgrade
|
| Accrued Expenses | - | 3 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 2.57 | 5.25 | 1.76 | 3.13 | 1.58 | 1.18 | Upgrade
|
| Long-Term Leases | 0.07 | - | - | 0.01 | - | - | Upgrade
|
| Total Liabilities | 2.64 | 5.25 | 1.76 | 3.14 | 1.58 | 1.18 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 225.85 | 130.79 | 65.81 | 61.87 | 60.22 | 47.87 | Upgrade
|
| Retained Earnings | -84.31 | -75.79 | -60.21 | -51.8 | -41.29 | -32.19 | Upgrade
|
| Comprehensive Income & Other | 0.01 | 0.04 | -0.01 | 0.01 | -0 | -0.01 | Upgrade
|
| Total Common Equity | 141.56 | 55.04 | 5.59 | 10.09 | 18.94 | 15.69 | Upgrade
|
| Shareholders' Equity | 141.56 | 55.04 | 5.59 | 10.09 | 18.94 | 15.69 | Upgrade
|
| Total Liabilities & Equity | 144.2 | 60.29 | 7.35 | 13.23 | 20.52 | 16.87 | Upgrade
|
| Total Debt | 0.1 | - | - | 0.01 | - | - | Upgrade
|
| Net Cash (Debt) | 143.57 | 60.21 | 7.27 | 13.11 | 20.3 | 16.74 | Upgrade
|
| Net Cash Growth | 2284.91% | 728.67% | -44.58% | -35.42% | 21.31% | 26.66% | Upgrade
|
| Net Cash Per Share | 22.08 | 15.89 | 2.63 | 5.15 | 8.14 | 7.64 | Upgrade
|
| Filing Date Shares Outstanding | 6.68 | 6.11 | 3.49 | 2.64 | 2.52 | 2.51 | Upgrade
|
| Total Common Shares Outstanding | 6.66 | 6.1 | 2.98 | 2.59 | 2.52 | 2.29 | Upgrade
|
| Working Capital | 141.52 | 55.04 | 5.58 | 10.04 | 18.94 | 15.62 | Upgrade
|
| Book Value Per Share | 21.25 | 9.02 | 1.87 | 3.90 | 7.52 | 6.85 | Upgrade
|
| Tangible Book Value | 141.56 | 55.04 | 5.59 | 10.09 | 18.94 | 15.69 | Upgrade
|
| Tangible Book Value Per Share | 21.25 | 9.02 | 1.87 | 3.90 | 7.52 | 6.85 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.